Above, Story Central Photo by Suzanne Lee, Save the Children: February 13, 2015. Sabatri, 23, cares for her son Dataram, 6 months, as he gets treated for pneumonia in the Trishuli District Hospital, Nepal.
A COMMENT FROM THE COORDINATOR
- SUBMIT YOUR ABSTRACTS for ATS 2019 by Jan 30: The American Thoracic Society is now accepting late-breaking scientific abstracts for the ATS 2019 International Conference, May 17-22, 2019, in Dallas, TX. Please note that case reports and research previously submitted in November 2018 will not be accepted. See complete submission details and guidelines here.
- CALL FOR PROPOSALS: Sida/ JPIAMR, submit by Feb 15: The Swedish International Development Cooperation Agency (Sida) is supporting the 2019 call for proposals from the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) for researchers from 30 African countries. The call promotes projects with partners and impact in low and middle-income countries (LMICs) in Asia and Africa. For more information, click here.
DEEP BREATHS: BLOGS FROM PIN MEMBERS
If we want a more equitable world, we need to tackle Respiratory Syncytial Virus
by Keith Klugman, Director, Pneumonia, Bill & Melinda Gates Foundation
Many of us who work in global health were drawn to the field by a desire to create a more equitable world. It is this desire that fuels our efforts to level the playing field for children with respiratory illness at the Bill & Melinda Gates Foundation. Diseases like pneumonia caused by the Respiratory Syncytial Virus (RSV), though unknown to many, clearly demonstrate a troubling pattern of global inequity. For infants lucky enough to be born in wealthy countries with access to quality health care, RSV often manifests as nothing more than a bad cold, with mild symptoms like fever, congestion, cough and a runny nose; if the disease becomes more severe and leads to hospitalization for pneumonia, then death is very rarely the result. But for babies born in poorer countries without access to quality health care, these symptoms can become a matter of life-or-death.
Neha Thakur, 25, poses with her 7-month-old baby, Vanita. ©Gates Archive/Mansi Midha
RSV is a leading cause of childhood pneumonia and subsequent hospitalizations. By the age of two, most babies will have been infected with RSV, leading to an estimated 30 million RSV-associated infections in children under five each year and over 100,000 deaths worldwide. The vast majority of these deaths occur in low- and middle-income countries, where children lack access to basic health services. Despite this burden, RSV awareness remains low among policy-makers and even health care providers in many parts of the world. Increasing the health community’s understanding of this common infection – and the tools we need to fight it – will be critical to addressing RSV.
Another important part of tackling the RSV burden is increasing access to primary health care, including for expecting mothers. Quality antenatal care leads to better health outcomes for both moms and their babies – against RSV and many other threats to maternal and child health like malnutrition or low iron levels.
On a recent trip to India, I saw the incredible work the country has done to strengthen primary health care while expanding access to immunization for another serious cause of pneumonia: the pneumococcus. Since last year, India has introduced the Pneumococcal Conjugate Vaccine (PCV) into its routine immunization program in six high-burden states. With this rollout, millions more Indian children will be protected from life-threatening pneumonia.
Gayatri Ahirwar, Auxiliary Nurse Midwife, prepares a vaccination. ©Gates Archive/Mansi Midha
India’s investments in the PCV rollout have in turn helped bolster the country’s primary health care system. As part of the PCV rollout, the country has prioritized health worker training, data collection, disease surveillance, community outreach and record keeping. These assets will help ensure that people receive the care they need and that new vaccine innovations reach those who need them most.
India’s experience holds important lessons for other countries planning rollouts for PCV and — hopefully one day — an RSV vaccine. Stronger primary health care systems coupled with vaccine innovations can tip the scale toward a more equitable world for future generations. A world that gives all children – no matter where they live – a chance to grow and thrive.
A pregnant woman visits an Anganwadi Centre for a health check up. ©Gates Archive/Mansi Midha
Keith Klugman, MD, PhD, is the Director of Pneumonia at the Bill & Melinda Gates Foundation. He is a leading expert on antibiotic resistance in pneumonia pathogens and helped develop the pneumococcal vaccine. Prior to working at the foundation, Keith was the William H. Foege Professor of Global Health and Professor of Epidemiology in the Rollins School of Public Health at Emory University, as well as Professor of Medicine in the Division of Infectious Diseases at the Emory School of Medicine.
PNEUMONIA INNOVATIONS NETWORK MEMBER AND PARTNER UPDATES
University of Edinburgh's WPD 2018 Symposium talks now available
For those who wanted to attend the University of Edinburgh's WPD 2018 Symposium but were unable to, we have great news: recordings of the live stream talks for the event are now available! Access to session talks for the Edinburgh WPD2018 event can be found here.
Submit your abstracts for ATS 2019 by January 30
The American Thoracic Society is now accepting late-breaking scientific abstracts for the ATS 2019 International Conference, May 17‒22, in Dallas.
ATS is seeking recent, groundbreaking research advanced with major impact to the fields of pulmonary, critical care, or sleep medicine. Abstracts can report on any of the following:
- Basic, translational, and clinical science research
- Epidemiologic, social, biobehavioral, and psychosocial investigations
- Education and quality improvement projects
It is anticipated that fewer than 50 percent of the late-breaking abstracts submitted will be accepted. Please note that case reports and research previously submitted in November 2018 will not be accepted.
See complete submission details and guidelines by clicking here.
Abstract submission deadline: Wednesday, Jan. 30, 2019 at 5 p.m. ET
Submit your JPIAMR proposals by February 15
The Swedish International Development Cooperation Agency (Sida) is supporting the 2019 call for proposals from the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) with up to SEK 35 million (approx. 3,4 million Euro) for researchers from 30 African countries. Researchers in Africa* are invited to form or join transnational teams together with counterparts in Asia, Europe or North America to produce tools, technologies and methods for diagnostics and surveillance of antimicrobial resistance. The call specifically promotes projects with partners and impact in low and middle-income countries (LMICs) in Asia and Africa. Researchers from Asia are supported by funding from IDRC-Canada. Researchers from all fields of science, including social sciences, are welcome to apply.
Deadline for applications is February 15, 2019.
Approximately 20 million Euro will be available for funding transnational research projects through this 9th JPIAMR Call.
More information is available at https://www.jpiamr.eu/9thcall/.
*Researchers based in the following African countries will be eligible for support from Sida through the JPIAMR Call: Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Congo (Dem. Rep.), Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe. This list is based on the World Bank list of low-income countries in Africa and the list of African countries where Sida has bilateral development cooperation.
Submit your abstracts for the Influenza Vaccines for the World (IVW) 2019 Conference
IVW 2019 is the seventh international conference and exhibition in this important series of influenza vaccine meetings. The IVW conference series focuses on ‘Influenza Vaccination Issues.’ The IVW series is an international forum for world-renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.
The IVW 2019 Scientific Advisory Panel invites the influenza community worldwide to submit abstracts for consideration for inclusion in the IVW 2019 oral & poster scientific programmes. There will be an opportunity for late breaking oral abstracts at a later date to be advised.
The deadline for poster abstracts submissions is Friday, 8th March 2019.
For information on how to register, visit www.meetingsmanagement.com/ivw_2019